Semaglutide

What is Semaglutide?

Semaglutide is a prescription medication available under the brand names Ozempic, Wegovy, and Rybelsus. It belongs to a class of medicines called GLP-1 receptor agonists, which work similarly to a natural hormone in your body that helps control blood sugar and appetite. Your doctor may prescribe semaglutide to help manage type 2 diabetes, to help with weight loss if you have obesity or are overweight with other health problems, or to reduce your risk of heart attack and stroke if you have heart disease.

How Does Semaglutide Work?

Semaglutide works in several ways to improve your health. For diabetes, it helps your pancreas release insulin when your blood sugar is high, reduces the amount of sugar your liver makes, and slows down how quickly food leaves your stomach. This helps keep your blood sugar levels more stable throughout the day. For weight loss, semaglutide works on areas of your brain that control appetite and food cravings, helping you feel fuller longer and eat less. Many people taking semaglutide notice they think about food less often and feel satisfied with smaller portions. The medication also has benefits for your heart and blood vessels, helping to lower blood pressure and improve cholesterol levels.

How to Take Semaglutide

Semaglutide comes in two forms: an injection you give yourself once a week (Ozempic or Wegovy) or a pill you take once a day (Rybelsus). If you're using the injection, you'll inject it under your skin in your stomach, thigh, or upper arm using a pre-filled pen. You can take it any time of day, with or without food, but try to use it on the same day each week. Your doctor will start you on a low dose and gradually increase it over several weeks or months to help your body adjust and reduce side effects.

If you're taking the pill form (Rybelsus), you must follow special instructions: Take it first thing in the morning on an empty stomach with no more than 4 ounces of plain water. Swallow the pill whole—don't split, crush, or chew it. After taking it, wait at least 30 minutes before eating, drinking anything else, or taking other medications. These steps are very important because food and other drinks can prevent the medication from working properly.

If you miss a dose of the injection and it's been 5 days or less, take it as soon as you remember. If it's been more than 5 days, skip that dose and take your next dose on your regular day. If you miss a dose of the daily pill, just skip it and take your next dose the following morning—don't take two pills to make up for a missed dose.

Common Side Effects

The most common side effects of semaglutide affect your stomach and digestive system. Many people experience nausea, especially when first starting the medication or when the dose is increased. You might also have diarrhea, vomiting, constipation, or stomach pain. These side effects are usually mild to moderate and often improve after a few weeks as your body adjusts to the medication. To help manage nausea, try eating smaller meals, avoiding greasy or spicy foods, eating slowly, and staying hydrated. Some people find that ginger tea or eating bland foods like crackers can help.

Other common side effects include feeling tired, headaches, dizziness, and decreased appetite. You might also notice your heart beating a little faster than usual. If you're using the injection, you may have redness, itching, or mild pain at the injection site. Most people find these side effects manageable and they often decrease over time.

When to Call Your Doctor

Call your doctor right away if you experience severe stomach pain that doesn't go away, especially if it spreads to your back, as this could be a sign of pancreatitis (inflammation of the pancreas). Also contact your doctor immediately if you have signs of an allergic reaction such as rash, itching, swelling of your face or throat, severe dizziness, or trouble breathing.

Seek medical attention if you have symptoms of low blood sugar (if you're also taking insulin or certain diabetes pills), including shakiness, sweating, fast heartbeat, confusion, or feeling very hungry. Contact your doctor if you have severe nausea, vomiting, or diarrhea that won't stop, as this can lead to dehydration and kidney problems. Other symptoms that need prompt attention include signs of gallbladder problems (severe pain in your upper right stomach area, fever, yellowing of skin or eyes), vision changes, symptoms of thyroid problems (lump or swelling in your neck, hoarseness, trouble swallowing, shortness of breath), or thoughts of harming yourself.

Important Warnings and Precautions

Semaglutide has a boxed warning about thyroid tumors. In animal studies, semaglutide caused thyroid tumors, though it's not known if this happens in humans. Do not use semaglutide if you or any family members have ever had medullary thyroid cancer or a condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Tell your doctor right away if you notice a lump in your neck, hoarseness that doesn't go away, trouble swallowing, or shortness of breath.

If you're pregnant, planning to become pregnant, or breastfeeding, talk to your doctor. You should stop taking semaglutide at least 2 months before trying to get pregnant because it stays in your body for several weeks. Tell your doctor about all other medications you take, especially insulin, diabetes pills, blood thinners, or any medications for other conditions. If you have a history of pancreatitis, kidney disease, diabetic eye problems, depression, or digestive problems, make sure your doctor knows before starting semaglutide.

Store your semaglutide pens in the refrigerator until you first use them, then you can keep them at room temperature or continue refrigerating them for up to 56 days. Keep the cap on when not in use to protect from light. Never freeze semaglutide, and throw it away if it has been frozen. The oral tablets should be stored in their original bottle at room temperature. Always check that the liquid in the pen looks clear and colorless to slightly yellow before injecting—don't use it if it looks cloudy, colored, or has particles in it.

Semaglutide represents a significant advancement in the GLP-1 receptor agonist class, developed by Novo Nordisk as a long-acting analog of human glucagon-like peptide-1. The compound was engineered with specific structural modifications to extend its duration of action and improve its pharmacokinetic profile compared to native GLP-1, which has a half-life of only 1.5-2 minutes due to rapid degradation by dipeptidyl peptidase-4 (DPP-4) and renal clearance.

The FDA approved semaglutide under multiple brand names for distinct indications. Ozempic (subcutaneous injection) received approval in December 2017 as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, with an additional indication approved in January 2020 to reduce the risk of major adverse cardiovascular events (MACE) in adults with type 2 diabetes and established cardiovascular disease. Rybelsus (oral tablet) was approved in September 2019, marking a breakthrough as the first oral GLP-1 receptor agonist, addressing a significant unmet need for patients preferring non-injectable options. Wegovy (subcutaneous injection at higher doses) received FDA approval in June 2021 for chronic weight management in adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one weight-related comorbidity, and was later expanded to include pediatric patients aged 12 years and older with obesity.

More recently, the therapeutic applications of semaglutide have continued to expand. In March 2024, Wegovy received an additional indication for cardiovascular risk reduction in adults with established cardiovascular disease and either obesity or overweight, based on the landmark SELECT trial demonstrating a 20% reduction in major adverse cardiovascular events. Furthermore, in March 2024, the FDA approved Wegovy for the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) with moderate to advanced liver fibrosis in adults, representing the first pharmacologic treatment approved for this condition.

Semaglutide has become one of the most widely prescribed medications for both diabetes management and weight loss, with clinical trial data demonstrating superior efficacy compared to other GLP-1 agonists and conventional therapies. The SUSTAIN clinical trial program for diabetes and the STEP program for weight management have established semaglutide as a cornerstone therapy, with weight loss outcomes of 15-17% of body weight at the 2.4 mg dose, unprecedented for a pharmacologic intervention. The medication's impact extends beyond metabolic parameters, with demonstrated benefits in cardiovascular outcomes, quality of life measures, and obesity-related comorbidities including sleep apnea, fatty liver disease, and osteoarthritis symptoms.

The availability of both injectable and oral formulations provides flexibility in treatment approaches, though the oral formulation requires specific administration instructions (taken on an empty stomach with minimal water, followed by a 30-minute fast) to achieve adequate absorption. The once-weekly dosing schedule for injectable formulations has improved adherence compared to daily GLP-1 agonists, contributing to its widespread adoption in clinical practice.

Semaglutide is a long-acting GLP-1 receptor agonist with 94% structural homology to native human GLP-1. It functions as a selective agonist of the GLP-1 receptor, a G-protein coupled receptor expressed predominantly on pancreatic beta cells, gastrointestinal tissues, and specific regions of the central nervous system including the hypothalamus and brainstem.

Upon binding to GLP-1 receptors on pancreatic beta cells, semaglutide activates adenylyl cyclase through Gs protein coupling, leading to increased intracellular cyclic AMP (cAMP) levels. This cascade enhances glucose-dependent insulin secretion, meaning insulin release occurs only when blood glucose levels are elevated, thereby minimizing hypoglycemia risk. Simultaneously, semaglutide suppresses inappropriately elevated glucagon secretion from pancreatic alpha cells in a glucose-dependent manner, further contributing to glycemic control.

In the gastrointestinal tract, semaglutide slows gastric emptying by acting on GLP-1 receptors in the stomach and proximal small intestine, which delays nutrient absorption and contributes to postprandial glucose reduction. This mechanism also promotes satiety and reduces appetite. Centrally, semaglutide crosses the blood-brain barrier to activate GLP-1 receptors in appetite-regulating centers of the hypothalamus and brainstem, including the arcuate nucleus and area postrema, leading to reduced food intake and increased energy expenditure.

The extended half-life of semaglutide (approximately 1 week) is achieved through three key structural modifications: substitution of alanine with alpha-aminoisobutyric acid at position 8 protects against DPP-4 degradation; attachment of a C18 fatty diacid chain enables albumin binding; and substitution at position 34 further enhances albumin binding. These modifications result in sustained receptor activation and allow for once-weekly dosing, distinguishing it from shorter-acting GLP-1 agonists.

Type 2 Diabetes Mellitus

Ozempic (Subcutaneous Injection)

Starting Dose: 0.25 mg once weekly for 4 weeks (not a therapeutic dose; for gastrointestinal tolerability)

Titration Schedule:

• Week 1-4: 0.25 mg once weekly

• Week 5+: Increase to 0.5 mg once weekly (first therapeutic dose)

• If additional glycemic control needed after ≥4 weeks: Increase to 1 mg once weekly

• If additional glycemic control needed after ≥4 weeks: May increase to 2 mg once weekly (maximum dose)

Maintenance Dose: 0.5 mg, 1 mg, or 2 mg once weekly based on glycemic response and tolerability

Rybelsus (Oral Tablet)

Starting Dose: 3 mg once daily for 30 days

Titration Schedule:

• Days 1-30: 3 mg once daily

• Day 31+: Increase to 7 mg once daily

• If additional glycemic control needed after ≥30 days: Increase to 14 mg once daily (maximum dose)

Alternative Lower-Dose Regimen (for patients requiring lower doses):

• Days 1-30: 1.5 mg once daily

• Day 31+: Increase to 4 mg once daily

• If needed after ≥30 days: Increase to 9 mg once daily

Administration Instructions for Oral Semaglutide:

• Take on an empty stomach upon waking

• Swallow whole with no more than 4 ounces (120 mL) of plain water only

• Do not split, crush, or chew tablets

• Wait at least 30 minutes before eating, drinking, or taking other oral medications

• If dose is missed, skip and take next dose the following day

Special Considerations for Type 2 Diabetes

Patients with Chronic Kidney Disease: No dose adjustment required for any degree of renal impairment, including end-stage renal disease. For patients with type 2 diabetes and chronic kidney disease, maintenance doses of 0.5 mg or 1 mg once weekly are typically used.

Cardiovascular Risk Reduction: For patients with type 2 diabetes and established cardiovascular disease, follow standard titration to maintenance dose of 0.5 mg, 1 mg, or 2 mg once weekly.

Concomitant Insulin or Sulfonylurea Use: Consider reducing insulin or sulfonylurea dose to minimize hypoglycemia risk when initiating semaglutide.

Chronic Weight Management

Wegovy (Subcutaneous Injection)

Indication: Adults and pediatric patients aged 12 years and older with obesity (BMI ≥30 kg/m² for adults, ≥95th percentile for age and sex for pediatrics), or adults with overweight (BMI ≥27 kg/m²) with at least one weight-related comorbidity

Titration Schedule:

Dose Escalation Considerations:

• If patient cannot tolerate a dose during titration, consider delaying dose escalation by 4 weeks

• If patient cannot tolerate 2.4 mg maintenance dose, may temporarily decrease to 1.7 mg once weekly

• Discontinue if patient cannot tolerate 1.7 mg dose

• Evaluate weight loss after 16 weeks on 2.4 mg dose; discontinue if patient has not lost ≥5% of baseline body weight

Rybelsus (Oral Tablet) - Higher Dose Regimen for Weight Management

Titration Schedule:

Administration: Follow same strict fasting administration protocol as described for diabetes indication.

Cardiovascular Risk Reduction

Wegovy (Subcutaneous Injection)

Indication: Adults with established cardiovascular disease and either obesity or overweight

Dosing: Follow same titration schedule as chronic weight management (0.25 mg → 0.5 mg → 1 mg → 1.7 mg → 2.4 mg once weekly with 4-week intervals)

Maintenance Dose: 2.4 mg once weekly

Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Wegovy (Subcutaneous Injection)

Indication: Noncirrhotic MASH with moderate to advanced liver fibrosis (F2-F3) in adults

Dosing: Follow same titration schedule as chronic weight management

Maintenance Dose: 2.4 mg once weekly

Administration Guidelines

Subcutaneous Injection (Ozempic, Wegovy)

Injection Sites: Abdomen, thigh, or upper arm. Rotate injection sites with each dose.

Timing: Administer once weekly on the same day each week, at any time of day, with or without meals.

Missed Dose:

• If ≤5 days since missed dose: Administer as soon as possible, then resume regular weekly schedule

• If >5 days since missed dose: Skip missed dose and administer next dose on regularly scheduled day

Pen Preparation:

• Inspect solution; should be clear and colorless to slightly yellow

• Do not use if cloudy, discolored, or contains particles

• Attach new needle for each injection

• Prime pen before first use of each new pen

Storage:

• Unopened pens: Refrigerate at 36°F to 46°F (2°C to 8°C)

• In-use pens: May be stored at room temperature up to 86°F (30°C) for up to 56 days or refrigerated

• Protect from light; keep pen cap on when not in use

• Do not freeze; discard if frozen

Special Populations

Renal Impairment: No dose adjustment required for any degree of renal impairment, including end-stage renal disease.

Hepatic Impairment: No dose adjustment required for mild, moderate, or severe hepatic impairment.

Geriatric Patients (≥65 years): No dose adjustment required based on age alone. Clinical experience in patients ≥75 years is limited.

Pediatric Patients:

• Approved for weight management in patients ≥12 years with obesity

• Use same titration schedule as adults

• Safety and efficacy not established in pediatric patients with type 2 diabetes

Pregnancy: Discontinue semaglutide at least 2 months before planned pregnancy due to long washout period.

Transition Between Formulations:

• When switching from Ozempic to Wegovy or vice versa, consider current dose and indication

• When switching from oral to subcutaneous or vice versa, account for bioavailability differences

• Initiate new formulation after last dose of previous formulation on next scheduled dosing day

The clinical efficacy and safety of semaglutide have been established through extensive phase 3 clinical trial programs encompassing thousands of patients across multiple indications. The SUSTAIN (Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes) program evaluated subcutaneous semaglutide in type 2 diabetes, while the PIONEER program assessed oral semaglutide, and the STEP (Semaglutide Treatment Effect in People with obesity) program investigated weight management applications.

In the SUSTAIN trials, semaglutide demonstrated superior glycemic control compared to placebo and active comparators. SUSTAIN-6, a cardiovascular outcomes trial involving 3,297 patients with type 2 diabetes at high cardiovascular risk followed for 104 weeks, demonstrated a 26% reduction in the primary composite endpoint of major adverse cardiovascular events (HR 0.74, 95% CI 0.58-0.95, p<0.001 for non-inferiority). HbA1c reductions ranged from 1.4% to 1.8% across doses (0.5 mg and 1.0 mg weekly), with 67-73% of patients achieving HbA1c <7%. Weight loss of 4.3-6.5 kg was observed as a secondary benefit. SUSTAIN-7 directly compared semaglutide 0.5 mg and 1.0 mg to dulaglutide 0.75 mg and 1.5 mg, demonstrating superior HbA1c reduction (treatment difference -0.4% to -0.5%) and greater weight loss (treatment difference -2.3 to -3.6 kg) with semaglutide.

The PIONEER program established oral semaglutide as an effective alternative to injectable formulations. PIONEER-1 through PIONEER-10 enrolled over 9,500 patients across various clinical scenarios including monotherapy, combination therapy, and comparative effectiveness studies. Oral semaglutide 14 mg daily reduced HbA1c by 1.0-1.4% from baseline, with 55-69% of patients achieving HbA1c <7%. PIONEER-4 demonstrated non-inferiority of oral semaglutide 14 mg to subcutaneous liraglutide 1.8 mg daily for glycemic control, with superior weight loss (-4.4 kg vs -3.1 kg). PIONEER-6, a cardiovascular outcomes trial with 3,183 patients, confirmed cardiovascular safety with a hazard ratio of 0.79 (95% CI 0.57-1.11) for MACE, meeting non-inferiority criteria.

The STEP program revolutionized obesity pharmacotherapy by demonstrating unprecedented weight loss with semaglutide 2.4 mg weekly. STEP-1 enrolled 1,961 adults with obesity or overweight plus comorbidities, achieving mean weight loss of 14.9% with semaglutide versus 2.4% with placebo at 68 weeks (treatment difference -12.4%, p<0.001). Notably, 86.4% of semaglutide-treated participants lost ≥5% body weight, 69.1% lost ≥10%, and 50.5% lost ≥15%, compared to 31.5%, 12.0%, and 4.9% with placebo, respectively. STEP-2 specifically enrolled patients with type 2 diabetes and obesity, demonstrating 9.6% weight loss with semaglutide 2.4 mg versus 3.4% with placebo, along with HbA1c reduction of 2.0% versus 0.4%. STEP-3 combined semaglutide with intensive behavioral therapy, achieving 16.0% weight loss. STEP-4 evaluated weight maintenance after initial weight loss, showing that continuing semaglutide resulted in additional 7.9% weight loss compared to 6.9% weight regain with placebo switch.

The landmark SELECT (Semaglutide Effects on Heart Disease and Stroke in Patients with Overweight or Obesity) trial published in 2023 enrolled 17,604 adults aged ≥45 years with established cardiovascular disease and BMI ≥27 kg/m² without diabetes. Over a mean follow-up of 40 months, semaglutide 2.4 mg weekly reduced the primary endpoint of MACE by 20% (HR 0.80, 95% CI 0.72-0.90, p<0.001), with consistent benefits across cardiovascular death, non-fatal MI, and non-fatal stroke components. This trial established semaglutide as the first weight management medication with proven cardiovascular benefits, leading to FDA approval for cardiovascular risk reduction in March 2024.

Additional evidence supports semaglutide's benefits in metabolic dysfunction-associated steatohepatitis (MASH). A phase 2 trial in patients with biopsy-confirmed NASH demonstrated NASH resolution without worsening fibrosis in 59% of patients receiving semaglutide 0.4 mg daily versus 17% with placebo. Fibrosis improvement occurred in 43% versus 33%, respectively. These findings led to accelerated approval for MASH treatment in 2024, with confirmatory phase 3 trials ongoing.

Safety data from these extensive trials demonstrate a consistent adverse event profile dominated by gastrointestinal symptoms (nausea 20-44%, diarrhea 9-30%, vomiting 9-24%, constipation 11-24%), typically mild-to-moderate in severity and diminishing over time. Serious adverse events occurred at similar rates to comparators. Discontinuation rates due to adverse events ranged from 4-7% in diabetes trials to 4-7% in obesity trials, comparable to or lower than other GLP-1 agonists. Long-term safety data extending beyond 2 years support sustained efficacy without new safety signals emerging with continued treatment.

Absolute Contraindications

Personal or Family History of Medullary Thyroid Carcinoma (MTC): Semaglutide is contraindicated in patients with a personal or family history of MTC due to the risk of thyroid C-cell tumors observed in rodent studies. In animal studies, semaglutide caused dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures.

Multiple Endocrine Neoplasia Syndrome Type 2 (MEN 2): Contraindicated in patients with MEN 2, a hereditary condition associated with increased risk of MTC.

Hypersensitivity Reactions: Contraindicated in patients with a history of serious hypersensitivity to semaglutide or any excipients. Serious hypersensitivity reactions including anaphylaxis and angioedema have been reported.

Boxed Warning

Risk of Thyroid C-Cell Tumors: Semaglutide carries a Boxed Warning regarding thyroid C-cell tumors. In rodent studies, semaglutide caused thyroid C-cell tumors. It is unknown whether semaglutide causes thyroid C-cell tumors, including MTC, in humans, as human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined. Counsel patients regarding the potential risk and symptoms of thyroid tumors (neck mass, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or thyroid ultrasound is of uncertain value in patients treated with semaglutide.

Serious Warnings and Precautions

Acute Pancreatitis: Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists including semaglutide. In clinical trials, acute pancreatitis was confirmed in 0.3% of semaglutide-treated patients versus 0.1% of comparator-treated patients. Observe patients for signs and symptoms including persistent severe abdominal pain, sometimes radiating to the back, with or without vomiting. If pancreatitis is suspected, discontinue semaglutide promptly and do not restart if pancreatitis is confirmed. Consider alternative antidiabetic or weight management therapies in patients with a history of pancreatitis.

Diabetic Retinopathy Complications: In the SUSTAIN-6 trial, diabetic retinopathy complications were reported in 3.0% of semaglutide-treated patients versus 1.8% of placebo-treated patients. The increased risk was observed in patients with pre-existing diabetic retinopathy and was associated with rapid improvement in glycemic control. Patients with a history of diabetic retinopathy should be monitored for progression of diabetic retinopathy. The mechanism may relate to rapid glucose lowering in patients with poor baseline control.

Hypoglycemia: When used as monotherapy or with medications not known to cause hypoglycemia, semaglutide has a low risk of hypoglycemia. However, when used in combination with insulin or insulin secretagogues (e.g., sulfonylureas), the risk of hypoglycemia increases. In SUSTAIN trials, severe hypoglycemia occurred in 1.5% of semaglutide-treated patients receiving concomitant insulin or sulfonylurea versus 1.4% of comparators. Dose reduction of insulin or insulin secretagogue may be necessary when initiating semaglutide. Educate patients on hypoglycemia recognition and management.

Acute Kidney Injury: Acute kidney injury and worsening of chronic renal failure, sometimes requiring hemodialysis, have been reported postmarketing in patients treated with GLP-1 receptor agonists including semaglutide. Some events occurred in patients without known underlying renal disease. Most reported events occurred in patients experiencing nausea, vomiting, diarrhea, or dehydration. Monitor renal function in patients with renal impairment reporting severe gastrointestinal adverse reactions and in patients at risk for volume depletion.

Hypersensitivity Reactions: Serious hypersensitivity reactions (e.g., anaphylaxis, angioedema) have been reported with semaglutide. If hypersensitivity reactions occur, discontinue semaglutide, treat promptly per standard of care, and monitor until signs and symptoms resolve. Do not use in patients with a previous hypersensitivity reaction to semaglutide. Use caution in patients with a history of angioedema with other GLP-1 receptor agonists.

Acute Gallbladder Disease: In clinical trials, cholelithiasis was reported in 1.6% of semaglutide-treated patients versus 0.7% of placebo-treated patients. Cholecystitis was reported in 0.6% versus 0.2%, respectively. Substantial or rapid weight loss can increase the risk of cholelithiasis. If cholelithiasis is suspected, gallbladder studies and appropriate clinical follow-up are indicated.

Gastrointestinal Adverse Reactions: Semaglutide causes gastrointestinal adverse reactions, sometimes severe. In pooled data, gastrointestinal adverse reactions occurred in 44% of semaglutide-treated patients versus 24% of placebo-treated patients. Nausea (20-44%), diarrhea (9-30%), vomiting (9-24%), and constipation (11-24%) were most common. These reactions are usually mild to moderate in severity and diminish over time. However, severe cases have been reported, including cases requiring hospitalization. Instruct patients to report severe or persistent gastrointestinal symptoms. Consider dose reduction or temporary discontinuation if severe symptoms occur.

Suicidal Behavior and Ideation: In obesity trials, suicidal ideation was reported in 0.3% of semaglutide 2.4 mg-treated patients versus 0.1% of placebo-treated patients. Monitor patients for depression, suicidal thoughts or behavior, and unusual changes in mood. Discontinue semaglutide in patients who experience suicidal thoughts or behaviors. Avoid semaglutide in patients with a history of suicidal attempts or active suicidal ideation.

Ileus and Gastrointestinal Obstruction: Ileus, including paralytic ileus, and intestinal obstruction have been reported postmarketing in patients treated with semaglutide, some requiring hospitalization and surgical intervention. Use with caution in patients with a history of these conditions.

Common Adverse Effects

Gastrointestinal (Very Common, >10%):

• Nausea (20-44%): Most common adverse reaction, typically occurs during dose escalation, usually diminishes over 4-8 weeks

• Diarrhea (9-30%)

• Vomiting (9-24%)

• Constipation (11-24%)

• Abdominal pain (6-20%)

• Dyspepsia (5-9%)

• Gastroesophageal reflux disease (5-9%)

• Eructation (7-9%)

• Flatulence (4-7%)

• Gastritis (3-5%)

Metabolic:

• Decreased appetite (common)

• Hypoglycemia when combined with insulin or sulfonylureas (1.5-6%)

General:

• Fatigue (6-11%)

• Headache (6-9%)

• Dizziness (5-8%)

Injection Site Reactions (Subcutaneous Formulations):

• Injection site reactions (1-3%): erythema, pruritus, pain

Laboratory Abnormalities:

• Increased lipase (common, usually asymptomatic)

• Increased amylase (common, usually asymptomatic)

• Increased heart rate (mean increase 1-4 bpm)

Special Populations

Pregnancy (Category: Not formally classified; avoid use):Limited human data exist regarding semaglutide use in pregnancy. Animal reproduction studies showed adverse developmental outcomes at clinically relevant exposures. Poorly controlled diabetes in pregnancy increases maternal risk for diabetic ketoacidosis, pre-eclampsia, spontaneous abortions, preterm delivery, and delivery complications, and increases fetal risk for major birth defects, stillbirth, and macrosomia-related morbidity. Discontinue semaglutide at least 2 months before a planned pregnancy due to the long washout period (approximately 5 weeks based on half-life). Use alternative therapies for glycemic control during pregnancy.

Lactation:There are no data on the presence of semaglutide in human milk, effects on the breastfed infant, or effects on milk production. Semaglutide was present in milk of lactating rats. Due to the potential for serious adverse reactions in breastfed infants, consider the developmental and health benefits of breastfeeding along with the mother's clinical need for semaglutide and any potential adverse effects on the breastfed infant.

Pediatric Use:Safety and efficacy of semaglutide for weight management have been established in pediatric patients aged 12 years and older with obesity. Safety and efficacy have not been established in pediatric patients with type 2 diabetes or in pediatric patients younger than 12 years for any indication. Use in pediatric patients under 12 years is not recommended.

Geriatric Use:No overall differences in safety or efficacy were observed between patients ≥65 years and younger patients. However, clinical experience in patients ≥75 years is limited. No dose adjustment is recommended based on age alone, but consider age-related decline in renal function and increased risk of dehydration from gastrointestinal adverse effects.

Renal Impairment:No dose adjustment is required for patients with renal impairment, including end-stage renal disease. However, monitor patients with renal impairment experiencing severe gastrointestinal reactions for worsening renal function.

Hepatic Impairment:No dose adjustment is required for patients with hepatic impairment. Clinical experience in patients with severe hepatic impairment is limited.

Monitoring Parameters

• Glycemic control: HbA1c, fasting plasma glucose (for diabetes indication)

• Body weight: Monitor regularly (for weight management indication)

• Renal function: Monitor in patients with renal impairment or experiencing severe GI symptoms

• Signs/symptoms of pancreatitis: Persistent severe abdominal pain

• Signs/symptoms of thyroid tumors: Neck mass, dysphagia, dyspnea, persistent hoarseness

• Diabetic retinopathy: In patients with pre-existing retinopathy, especially with rapid glucose improvement

• Hypoglycemia symptoms: Particularly in patients on concomitant insulin or secretagogues

• Mental health: Depression, suicidal ideation (particularly in obesity patients)

• Gallbladder disease: Right upper quadrant pain, jaundice

• Heart rate: Baseline and periodic monitoring (mean increase 1-4 bpm observed)

• Hypersensitivity reactions: Rash, pruritus, angioedema, anaphylaxis

Drug Interactions Requiring Monitoring

• Insulin and insulin secretagogues: Increased hypoglycemia risk; dose reduction may be necessary

• Oral medications: Delayed gastric emptying may affect absorption; monitor for altered efficacy

• Warfarin/coumarin derivatives: Monitor INR more frequently during initiation and dose changes

Pharmacokinetics

Semaglutide exhibits favorable pharmacokinetic properties that enable once-weekly subcutaneous dosing or once-daily oral administration. Following subcutaneous injection, semaglutide is absorbed slowly with maximum plasma concentrations (Tmax) reached in 1-3 days. The absolute bioavailability of subcutaneous semaglutide is 89%. For oral semaglutide (Rybelsus), absorption occurs in the stomach facilitated by the co-formulated absorption enhancer sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC), which increases local pH and enhances paracellular absorption. Oral bioavailability is approximately 0.4-1%, significantly lower than subcutaneous administration, necessitating higher oral doses to achieve therapeutic plasma levels. Food significantly reduces oral semaglutide absorption, requiring administration in a fasting state.

The volume of distribution of semaglutide is approximately 12.5 liters, indicating limited distribution beyond the vascular and interstitial spaces. Semaglutide exhibits high plasma protein binding (>99%), primarily to albumin via the fatty diacid side chain. This extensive albumin binding protects the molecule from renal filtration and enzymatic degradation, contributing to its extended half-life. The elimination half-life is approximately 1 week (approximately 165-184 hours) for subcutaneous administration, enabling steady-state concentrations to be achieved after 4-5 weeks of once-weekly dosing. Oral semaglutide has a similar half-life, supporting once-daily dosing.

Semaglutide is metabolized via proteolytic cleavage of the peptide backbone and sequential beta-oxidation of the fatty acid side chain, similar to endogenous proteins and fatty acids. The primary metabolite is the des-amido semaglutide, which is pharmacologically inactive. Metabolism occurs through ubiquitous pathways rather than specific cytochrome P450 enzymes, resulting in minimal potential for drug-drug interactions via metabolic pathways. Excretion occurs primarily via urine (53%) and feces (47%), with only 3% of the dose excreted as intact semaglutide. No dose adjustment is required for patients with renal impairment, including end-stage renal disease, or for patients with hepatic impairment.

Pharmacodynamics

Semaglutide demonstrates dose-dependent glucose-lowering effects through multiple mechanisms. In clinical studies, semaglutide 0.5 mg and 1 mg once weekly reduced HbA1c by 1.4-1.6% and 1.5-1.8% respectively from baseline in patients with type 2 diabetes. Fasting plasma glucose reductions of 28-41 mg/dL and postprandial glucose reductions of 36-58 mg/dL have been observed. The glucose-dependent mechanism of insulin secretion results in a low intrinsic risk of hypoglycemia when used as monotherapy.

Weight loss effects are substantial and dose-dependent. In the STEP trials, semaglutide 2.4 mg once weekly resulted in mean weight loss of 14.9-17.4% of baseline body weight over 68 weeks in patients with obesity, compared to 2.4-3.2% with placebo. Weight loss begins within the first weeks of treatment and continues progressively during dose escalation and maintenance phases. The weight reduction is attributed to decreased caloric intake (approximately 500-1000 kcal/day reduction) through enhanced satiety, reduced appetite, and decreased food cravings, rather than increased energy expenditure.

Cardiovascular effects have been demonstrated in dedicated outcome trials. The SUSTAIN-6 trial showed a 26% reduction in major adverse cardiovascular events (MACE: cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in patients with type 2 diabetes at high cardiovascular risk. The SELECT trial demonstrated a 20% reduction in MACE in patients with established cardiovascular disease and obesity or overweight without diabetes. These benefits appear to be mediated through multiple pathways including weight loss, blood pressure reduction (2-7 mmHg systolic), improvements in lipid profiles, reduction in inflammatory markers, and potential direct cardioprotective effects.

Drug Interactions

Semaglutide has a low potential for pharmacokinetic drug interactions due to its metabolism via proteolytic pathways rather than cytochrome P450 enzymes. However, the delay in gastric emptying can affect the absorption of concomitantly administered oral medications. In pharmacokinetic studies, semaglutide did not significantly affect the overall exposure (AUC) of orally administered medications including atorvastatin, digoxin, lisinopril, metformin, or oral contraceptives, though minor changes in Tmax were observed.

The most clinically significant interaction occurs with insulin and insulin secretagogues (sulfonylureas, meglitinides), which may increase the risk of hypoglycemia. Dose reduction of these agents is typically required when initiating semaglutide. Patients taking warfarin or other coumarin derivatives should have more frequent INR monitoring during semaglutide initiation and dose titration due to potential effects on absorption. The absorption of oral semaglutide (Rybelsus) is highly sensitive to co-administration with food, other medications, or beverages, requiring strict adherence to fasting administration protocols.